<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243304</url>
  </required_header>
  <id_info>
    <org_study_id>s61477</org_study_id>
    <nct_id>NCT04243304</nct_id>
  </id_info>
  <brief_title>Synaptic Density and Progression of Parkinson's Disease.</brief_title>
  <official_title>Longitudinal Measurement of Synaptic Density to Monitor Progression of Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIM: To assess synaptic density and to investigate the potential relationship of regional
      synaptic loss with motor and non-motor symptoms and with disease progression in the human
      brain in vivo in patients with PD.

      DESIGN: We will include 30 PD patients and 20 healthy controls. All subjects will undergo a
      clinical examination, with comprehensive assessment of motor and non-motor symptoms, and
      imaging evaluation consisting of 11C-UCB-J PET-CT and 18F-FE-PE2I PET-MR at baseline and
      after 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Longitudinal study design (2 years follow up) where results of SV2A PET/CT, PE2I PET/MR and clinical rating scales are compared between PD patients and healthy controls.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline differences in synaptic density.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the baseline evaluation.</time_frame>
    <description>Baseline differences (%) in synaptic density between patients and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlations between clinical scores and synaptic density.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Correlations between clinical scores and synaptic density in the patient group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in the rate of decline of synaptic density.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Differences (%) in the rate of decline of synaptic density between patients and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlations between progression of the clinical scores and decline of synaptic density.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Correlations between progression of the clinical scores and decline of synaptic density in the patient group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline differences in DAT levels.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the baseline evaluation.</time_frame>
    <description>Baseline differences (%) in DAT levels between patients and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between clinical scores and DAT levels.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Correlations between clinical scores and DAT levels in the patient group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the rate of decline of global and DAT levels.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Differences (%) in the rate of decline of global and DAT levels between patients and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between progression of the clinical scores and decline of DAT levels.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Correlations between progression of the clinical scores and decline of DAT levels in the patient group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>PD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At baseline and 2-year follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At baseline and 2-year follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>11C-UCB-J PET-CT</intervention_name>
    <description>Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>PD patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-PE2I PET-MR</intervention_name>
    <description>Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>PD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PD diagnosis based on MDS clinical diagnostic criteria for Parkinson's disease

          -  Less than 5 years disease duration since motor symptom onset according to the patient

          -  Hoehn-Yahr stage 1 or 2 in medication ON state

          -  Capacity to understand the informed consent form

        Exclusion Criteria:

          -  Neuropsychiatric diseases other than PD

          -  Major internal medical diseases

          -  Relevant abnormalities on MR brain

          -  History of alcohol or drug abuse

          -  Contraindications for MR

          -  Pregnancy

          -  Previous participation in other research studies involving ionizing radiation with &gt; 1
             mSv over past 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Vandenberghe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wim Vandenberghe, MD, PhD</last_name>
    <phone>+3216344280</phone>
    <email>wim.vandenberghe@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aline Delva, MD</last_name>
    <phone>+3216345771</phone>
    <email>aline.delva@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Delva, Dr.</last_name>
      <phone>+3216345771</phone>
      <email>aline.delva@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Aline Delva, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wim Vandenberghe, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>PET</keyword>
  <keyword>UCB-J</keyword>
  <keyword>PE2I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Needs to be decided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

